Last reviewed · How we verify
On ibalizumab treatment
At a glance
| Generic name | On ibalizumab treatment |
|---|---|
| Also known as | Ibalizumab |
| Sponsor | Theratechnologies |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab
- Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- 10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults (PHASE1)
- Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1 (PHASE3)
- Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- On ibalizumab treatment CI brief — competitive landscape report
- On ibalizumab treatment updates RSS · CI watch RSS
- Theratechnologies portfolio CI